Consumables are improving; financing risk still owns the equity debate
Record consumables revenue and SPRQ-Nx adoption are the constructive signals, but flat total revenue, weak instrument economics, negative cash flow, and debt above cash leave the underwrite dependent on a back-half acceleration and a credible route to breakeven.
- Price
- $1.56 delayed close
- Posture
- Preliminary watchlist underwrite
- Next proof
- Consumables, pull-through, margin, burn
- Valuation
- EV/revenue screen; DCF not reliable
12-month bear / base / bull
Bear$0.25-$0.65
- 2027 revenue
- $170m-$180m
- TEV / revenue
- 3.0x-3.5x
- Return
- -84% to -58%
- Operating
- FY2026 misses; placements and pull-through remain weak
- Capital
- Cash burn forces an unfavorable financing or dilution
Base$1.30-$1.90
- 2027 revenue
- $185m-$200m
- TEV / revenue
- 4.5x-5.0x
- Return
- -17% to +22%
- Operating
- FY2026 lands within guide; 2027 growth approaches consensus
- Capital
- Runway remains adequate, but dilution risk stays visible
Bull$2.30-$3.10
- 2027 revenue
- $205m-$220m
- TEV / revenue
- 5.5x-6.3x
- Return
- +47% to +99%
- Operating
- SPRQ-Nx lifts consumables, pull-through, and gross margin
- Capital
- Lower burn supports a credible path toward breakeven
Current indicator: $1.56 sits inside the Base range; the external analyst target range is $1.50-$3.00.Forward revenue × TEV/revenue, less net debt; screen-grade, not a DCF
Scenario mechanics: The ranges use approximately $430m of provider-reported debt less cash and the current 310.6m basic shares as the starting equity bridge. They are monitoring ranges rather than price targets and do not yet model convertible-note outcomes or future equity issuance.
Valuation method and decision gate
DCFNot usable
- 2027 EBITDA
- -$117.7m consensus
- EPS horizon
- Negative through 2029
- Problem
- Terminal value and financing assumptions dominate
EV / revenue4.72x
- Basis
- 2027E revenue of $193.8m
- Current TEV
- $915.0m
- Role
- Screen only, not intrinsic value
Capital gate$430m
- Debt less cash
- Approximate provider bridge
- Q1 cash use
- $44.7m operating
- Requirement
- Refinancing and fully diluted share cases
Conclusion: Do not manufacture a DCF target from unsupported breakeven and terminal-margin assumptions.Method review recorded in the research workspace
| # | KPI | Baseline | Next threshold | Status | Investor read | Source |
|---|---|---|---|---|---|---|
| 1 | FY2026 revenue guide | $165m-$175m | Back-half acceleration | Cut | Q1 run-rate does not by itself support the full year. | ER |
| 2 | Consumables revenue | $21.8m; +9% | Accelerate with SPRQ-Nx | Record | The cleanest recurring-growth signal. | ER p.2 |
| 3 | Instrument revenue | $9.7m; -12% | Stabilize ASP and placements | Weak | Funding and elongated sales cycles remain constraints. | 10-Q |
| 4 | Revio pull-through | ~$229k annualized | Exceed $236k comparator | Down | Must improve for the installed-base thesis to work. | ER p.2 |
| 5 | Non-GAAP gross margin | 37% | FY26 guide 41%-44% | Below guide | Compute, promotion, inventory and warranty pressured Q1. | ER |
| 6 | Operating cash use | $44.7m in Q1 | Sequential reduction | High | Runway depends on material operating improvement. | 10-Q |
| 7 | Debt / cash | $706m / $276m | Funded path through breakeven | Gate | Debt and possible dilution prevent a clean equity bridge. | CIQ key stats |
| 8 | 2027 TEV / revenue | 4.72x | Growth/margin-adjusted peer check | Screen | Only usable after financing and execution risk are kept explicit. | CIQ |
What changed after Q1
SPRQ-Nx
Commercial shipments began; PacBio says multi-use cells can reduce sequencing costs by up to 30% for high-volume Revio customers.
Clinical use
Management describes clinical adoption as the principal consumables-growth engine; economic conversion is still unproven.
Balance sheet
The short-read asset sale added $48.1m of net cash proceeds, but does not solve recurring operating burn.
Prove / kill framework
Prove
Consumables accelerate, pull-through rebounds, FY gross-margin guidance is delivered, and quarterly burn falls.
Kill
Another guide cut, persistent Vega/Revio weakness, margin slippage, or financing before an evidenced breakeven bridge.
Missing
Q1 call transcript, backlog/orders, peer set, diluted financing cases, and a forecast through positive FCFF.
Source register
ER-Q1-26Pacific Biosciences Q1 2026 earnings release; reported KPIs, non-GAAP reconciliations, and FY guidance.
10Q-Q1-26Quarter ended March 31, 2026; GAAP financials, liquidity, debt, cash flow, and risk disclosures.
CIQ-EST/KEY/MULT-0712S&P Capital IQ exports dated July 12, 2026; delayed price, consensus, capitalization, and multiples. Licensed provider data.
PR-SPRQ-0526PacBio product release; company claims about SPRQ-Nx performance and sequencing cost.
Research posture: Preliminary watchlist underwrite. Evidence confidence is moderate for reported financials and low-to-moderate for the long-range equity outcome. No investment rating or intrinsic target is asserted. The underlying thesis, QA, valuation-method, and source trackers remain in the local research workspace.